https://teniposideinhibitor.co....m/routes-with-the-hi
But, a somewhat bad prognosis has been reported in older patients with CHL, together with efficacy and tolerability for the ABVD regimen is not totally elucidated. We retrospectively investigated the outcomes in patients with CHL addressed with ABVD at our institute. Techniques Twenty-five customers had been evaluated; 14 had been ≤60 years, and 11 had been 60 years of age (older team). Outcomes The ABVD amounts had been reduced in all clients in the older group; the median average relative dose streng
Like
Comment
Share
